(Total Views: 645)
Posted On: 03/05/2017 10:57:14 AM
Post# of 30066
Hoping multi-billionaire Heng Fai moves MANF into human trials in gene therapy for Parkinson's disease as well as tissue repair in retinal regenerative therapy. Herantis Pharma is moving CDNF, MANF's complimentary neurotrophic factor, into human trials for Parkinson' Disease in the first half of 2017. The diabetes angle with MANF is also interesting.
http://herantis.com/pipeline/cdnf-in-parkinsons-disease/
http://science.sciencemag.org/content/353/6294/aaf3646.full
Also, ESS is ready for a pivotal approval trial. Hopefully Heng Fai and AMBS can work together to get this moving once again.
https://clinicaltrials.gov/ct2/show/NCT016554...amp;rank=2
Avant assets, Eltoprazine also hold promise. I also like potential for the natural-based products SeD wants to move into AMBS. SeD's current diabetes supplement Emulin will be a big seller.
http://herantis.com/pipeline/cdnf-in-parkinsons-disease/
http://science.sciencemag.org/content/353/6294/aaf3646.full
Also, ESS is ready for a pivotal approval trial. Hopefully Heng Fai and AMBS can work together to get this moving once again.
https://clinicaltrials.gov/ct2/show/NCT016554...amp;rank=2
Avant assets, Eltoprazine also hold promise. I also like potential for the natural-based products SeD wants to move into AMBS. SeD's current diabetes supplement Emulin will be a big seller.
(3)
(0)
